Keyphrases
Abdominal
50%
Abdominal CT
16%
Carbohydrate Antigen 125 (CA125)
16%
Cervical Cancer
50%
Cervical Cancer Diagnosis
50%
Cervical Cancer Patients
33%
Cervical Cancer Prevention
100%
Cervical Cancer Screening
66%
Cesarean Hysterectomy
50%
Confidence Interval
27%
Developing Countries
25%
Diagnostic Test
16%
Endometrioid
50%
Fibrinogen
50%
Fibroids
50%
Free Survival
50%
General Hospital
16%
Gynecologic Oncologist
57%
Hazard Ratio
38%
High-risk Endometrial Cancer
50%
High-risk Human Papillomavirus (HR-HPV)
25%
Indonesia
100%
January 2017
16%
Large Hospital
50%
Large Uterine Fibroids
50%
Liquid-based Cytology
16%
Lymphovascular Invasion
50%
Malignant Ovarian Tumor
50%
Menopause
16%
Multipara
16%
Negative Predictive Value
16%
Neutrophil-to-lymphocyte Ratio
50%
Normal BMI
16%
Obstetrics and Gynaecology
50%
Ovarian Cancer
66%
Ovarian Malignancy
16%
Overall Survival
77%
Pathology Examination
16%
Pelvic CT
50%
Positive Predictive Value
16%
Prognostic Factors
19%
Prognostic Value
50%
Progression-free Survival
27%
Ratio Level
50%
Sensitivity Specificity
16%
Silent Killer
16%
Surabaya
16%
Tertiary Hospital
47%
Tertiary Referral Hospital
50%
Tumor Patients
50%
Medicine and Dentistry
Biopsy Technique
8%
Body Mass Index
23%
CA-125
16%
Cancer
22%
Cancer Diagnosis
50%
Cancer Prevention
8%
Cancer Therapy
50%
Cancer Treatment
8%
Cervical Cancer
75%
Cervical Cancer Prevention
58%
Cervical Cancer Screening
50%
Cervical Screening
25%
Clinical Stage
7%
Cross Sectional Study
16%
Diagnostic Test
16%
Disease Free Survival
28%
Diseases
70%
Fibrinogen
50%
General Practitioner
12%
Gynecological Oncology
8%
Hazard Ratio
38%
Liquid-Based Cytology
25%
Log Rank Test
7%
Low and Middle Income Countries
8%
Lymphocyte
50%
Malignant Neoplasm
50%
Medical Record
16%
Myometrium
7%
Neutrophil
50%
Oncologist
57%
Outpatient
16%
Ovarian Cancer
66%
Ovarian Tumor
50%
Overall Survival
77%
Papanicolaou Stain
37%
Patient Referral
50%
Pelvis
50%
Pfannenstiel Incision
7%
Primigravida
7%
Prognostic Factor
35%
Progression Free Survival
27%
Sensitivity and Specificity
16%
Stage 3 Cancer
8%
Survival Time
7%
Therapy Delay
8%
Uterine Cancer
50%
Uterine Fibroid
50%
Uterine Myomectomy
50%
Wart Virus
50%
Wart Virus Vaccine
25%
